Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Also known as immunotoxin
TP-38 · 2 trials · 2 indications
% patients alive
| Arm | Type | Description |
|---|---|---|
| 1 | EXPERIMENTAL | 40 mL of TP-38 at a 100 nanograms/mL concentration |
| TP38 50 ng/mL | EXPERIMENTAL | - |
| TP38 100 ng/mL | EXPERIMENTAL | - |
| Name | Type | Description |
|---|---|---|
| TP-38 | DRUG | TP-38 is a recombinant chimeric protein composed of the epidermal growth factor (EGFR) binding ligand (TGF-α)and a genetically engineered form of the Pseudomonas exotoxin, PE-38. |
| TP38 | DRUG | recombinant chimeric protein |
Inclusion Criteria: The patients must fulfill all the following criteria: * Previous histologically-confirmed diagnosis of primary GBM (glioblastoma multiforme, glioma grade 4 at time of first diagnosis). * Histologically-confirmed and MRI diagnosed recurrent or progressive GBM after previous rese...
TP-38 is an investigational small molecule being studied for the treatment of glioblastoma multiforme, including recurrent glioblastoma multiforme. It is in Phase 2 clinical development for these indications.
TP-38 is a small molecule therapeutic being developed for oncology. Its specific molecular target has not been disclosed in available clinical trial information.
TP-38 is being developed by Teva Pharmaceutical Industries Limited, a company traded on the New York Stock Exchange under the ticker TEVA.
TP-38 is in Phase 2 clinical development. It has completed two Phase 2 trials, and it remains an investigational drug that is not approved for commercial use.
TP-38 has been studied in two completed Phase 2 trials: NCT00071539 and NCT00104091. Both trials enrolled 56 participants each and evaluated the drug in patients with glioblastoma multiforme, including recurrent disease.
TP-38 is also known by the name TP38. It is a distinct investigational agent being developed by Teva Pharmaceutical Industries Limited for glioblastoma multiforme.